ViewRay Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ViewRay stock.
View analyst ratings for ViewRay or view top-rated stocks.

Wall Street analysts have given ViewRay a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ViewRay wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ViewRay is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for ViewRay.

ViewRay, Inc. (NASDAQ:VRAY) posted its quarterly earnings results on Thursday, May, 6th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.01. ViewRay had a negative trailing twelve-month return on equity of 69.14% and a negative net margin of 183.76%.
View ViewRay's earnings history.

ViewRay's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VRAY shares have increased by 243.2% and is now trading at $5.80.
View which stocks have been most impacted by COVID-19.

7 equities research analysts have issued 1 year price targets for ViewRay's stock. Their forecasts range from $3.00 to $7.00. On average, they anticipate ViewRay's share price to reach $4.86 in the next twelve months. This suggests that the stock has a possible downside of 16.3%.
View analysts' price targets for ViewRay or view top-rated stocks among Wall Street analysts.

5 employees have rated ViewRay CEO Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among ViewRay's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ViewRay include InMode (INMD), Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), Semler Scientific (SMLR), Stereotaxis (STXS), Zynex (ZYXI), Edap Tms (EDAP), Second Sight Medical Products (EYES), Movano (MOVE), BioSig Technologies (BSGM) and IRIDEX (IRIX).
View all of VRAY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

ViewRay's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (12.82%), Hudson Executive Capital LP (9.13%), Pura Vida Investments LLC (5.96%), BlackRock Inc. (5.94%), Bamco Inc. NY (1.98%) and Tamarack Advisers LP (1.51%). Company insiders that own ViewRay stock include International Ltd Fosun, James F Dempsey, Scott William Drake and Shahriar Matin.
View institutional ownership trends for ViewRay.

VRAY stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Millennium Management LLC, Goldman Sachs Group Inc., Royce & Associates LP, Credit Suisse AG, Kahn Brothers Group Inc. DE, and Hodges Capital Management Inc..
View insider buying and selling activity for ViewRay or view top insider-selling stocks.

VRAY stock was bought by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, Artisan Partners Limited Partnership, Pura Vida Investments LLC, Hudson Executive Capital LP, BlackRock Inc., Bamco Inc. NY, Point72 Asset Management L.P., and Dimensional Fund Advisors LP. Company insiders that have bought ViewRay stock in the last two years include Scott William Drake, and Shahriar Matin.
View insider buying and selling activity for ViewRay or or view top insider-buying stocks.

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRAY stock can currently be purchased for approximately $5.80.

ViewRay has a market capitalization of $938.09 million and generates $57.02 million in revenue each year. The company earns $-107,910,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.

ViewRay employs 236 workers across the globe.

The official website for ViewRay is www.viewray.com.

ViewRay is headquartered at 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146.

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]